IGC Pharma, Inc.
IGC · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $191 | $328 | $330 | $257 |
| % Growth | -41.8% | -0.6% | 28.4% | – |
| Cost of Goods Sold | $92 | $174 | $176 | $153 |
| Gross Profit | $99 | $154 | $154 | $104 |
| % Margin | 51.8% | 47% | 46.7% | 40.5% |
| R&D Expenses | $1,588 | $851 | $997 | $852 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,410 | $1,208 | $569 | $1,130 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,998 | $2,059 | $1,566 | $1,982 |
| Operating Income | -$2,899 | -$1,905 | -$1,412 | -$1,878 |
| % Margin | -1,517.8% | -580.8% | -427.9% | -730.7% |
| Other Income/Exp. Net | $1,078 | $306 | $215 | $49 |
| Pre-Tax Income | -$1,821 | -$1,599 | -$1,197 | -$1,829 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,821 | -$1,599 | -$1,197 | -$1,829 |
| % Margin | -953.4% | -487.5% | -362.7% | -711.7% |
| EPS | -0.02 | -0.019 | -0.016 | -0.024 |
| % Growth | -3.6% | -23.7% | 33.9% | – |
| EPS Diluted | -0.02 | -0.019 | -0.016 | -0.024 |
| Weighted Avg Shares Out | 90,458 | 83,027 | 76,517 | 77,633 |
| Weighted Avg Shares Out Dil | 90,458 | 83,027 | 76,517 | 77,633 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $119 | $141 | $154 | $157 |
| EBITDA | -$1,702 | -$1,764 | -$1,258 | -$1,721 |
| % Margin | -891.1% | -537.8% | -381.2% | -669.6% |